Literature DB >> 16769417

Paraneoplastic syndromes affecting the nervous system.

Robert B Darnell1, Jerome B Posner.   

Abstract

The paraneoplastic neurologic disorders (PND) are a diverse group of diseases characterized by the presence of neurologic dysfunction in the setting of a remote cancer. PND can affect almost any part of the nervous system, and are most commonly associated with lung cancer (small cell) and gynecologic tumors. Laboratory studies have demonstrated that an autoimmune response links the neurologic disorder and the cancer, and established a model whereby the cancer is believed to initiate the syndrome by expressing a protein antigen normally expressed in the nervous system, leading to anti-tumor immune response followed by autoimmune neurologic symptoms. We review the currently known PND and their pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769417     DOI: 10.1053/j.seminoncol.2006.03.008

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  39 in total

Review 1.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

2.  An uncommon paraneoplastic Ri-positive opsoclonus-myoclonus-like syndrome and stiff-person syndrome with elevated glutamate/GABA ratio in the cerebrospinal fluid after breast cancer.

Authors:  A Thümen; A Moser
Journal:  J Neurol       Date:  2010-02-23       Impact factor: 4.849

Review 3.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

4.  Immunotherapy for Alzheimer disease.

Authors:  Gunnar K Gouras
Journal:  MAbs       Date:  2009-03-11       Impact factor: 5.857

5.  Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.

Authors:  M Hardy-Werbin; O Arpí; A Taus; P Rocha; D Joseph-Pietras; L Nolan; S Danson; R Griffiths; M Lopez-Botet; A Rovira; J Albanell; C H Ottensmeier; E Arriola
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

Review 6.  Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.

Authors:  Julie R Brahmer; Drew M Pardoll
Journal:  Cancer Immunol Res       Date:  2013-07-22       Impact factor: 11.151

7.  Paraneoplastic extralimbic encephalitis associated with thymoma: a case report.

Authors:  Masato Aragaki; Yasuaki Iimura; Kenichi Teramoto; Nagato Sato; Kazuyuki Hirose; Naoto Hasegawa
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-04-24       Impact factor: 1.520

Review 8.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Paraneoplasia, cancer development and immunity: what are the connections?

Authors:  Louis Chesler
Journal:  Nat Rev Cancer       Date:  2014-07       Impact factor: 60.716

10.  The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells.

Authors:  Kevin J O'Donovan; Jennifer Diedler; Graeme C Couture; John J Fak; Robert B Darnell
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.